Dexcom (DXCM) Stock Is Plunging on an ‘Execution Miss.' What Is Really Going On?

Dexcom (NASDAQ:DXCM) stock is down over 40% after reporting disappointing revenue for the second quarter.It also lowered guidance for the rest of the year.The problem lies with its Stelo continuous glucose monitor. The company is delaying the device’s launch as it builds inventory.Dexcom earned $143.5 million, 35 cents per share fully diluted, on revenue of $1 billion. But it guided toward slower growth, just 1% to 3% for the third quarter, and 11% to 13% for the year.DXCM stock opened this morning at about ...